Eyecure Therapeutics, Inc. (Jiangsu) – Trademark Portfolio

Entity Type: 03

Eyecure Therapeutics, Inc. (Jiangsu) has 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO). Filings span 3 Nice Classification classes, led by Class 35 (Advertising & Business) and Class 42 (Computer & Scientific). This trademark owner is based in District, Wuxi,.

7 ChangJiang Road, (Room 502, Building

1, Science and Technology Park), Xinwu

District, Wuxi, 214101 , CN

3 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

OCUCYTE
OCUCYTE
Cancelled 2018
OCUCYTE
OCUCYTE
Abandoned 2018
OCUCYTE
OCUCYTE
Cancelled 2018

Trademark Classifications

Eyecure Therapeutics, Inc. (Jiangsu)'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

35
Advertising & Business (1 filing)

Advertising; business management; business administration; office functions

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does Eyecure Therapeutics, Inc. (Jiangsu) have?

Eyecure Therapeutics, Inc. (Jiangsu) has 3 U.S. trademarks filed with the USPTO.

What trademark classes does Eyecure Therapeutics, Inc. (Jiangsu) file in?

Eyecure Therapeutics, Inc. (Jiangsu) files trademarks across 3 Nice Classification classes. The most active classes are Class 35 (Advertising & Business), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 35 covers advertising; business management; business administration; office functions.

What is Eyecure Therapeutics, Inc. (Jiangsu)'s trademark registration success rate?

Eyecure Therapeutics, Inc. (Jiangsu) has a 0% trademark registration rate, with 0 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.